Heart Failure

NATIONAL HARBOR, Md. — In a DELIVER subgroup analysis, dapagliflozin conferred similar benefit in patients with HF with improved ejection fraction prior to trial enrollment compared with those with consistently high EF.

NATIONAL HARBOR, Md. — A novel speech analysis system was able to detect impending heart failure events in ambulatory patients with congestive HF more than 3 weeks ahead of time, a speaker reported.

A database review showed left atrial appendage closure with the Watchman device is safe in adults with HF and atrial fibrillation, who experienced in-hospital mortality and CV complication rates similar to those without HF.

In adults with HF, empagliflozin was associated with a reduction in new macroalbuminuria in patients with macroalbuminuria at baseline compared with placebo.

Cannabinoids are widely available for therapeutic and recreational use, but data are limited regarding drug-drug interactions — particularly with cardiovascular medications, according to experts.

Telemedicine interventions that include remote disease monitoring and remote consultations may reduce short-term CV-related hospitalization and death risk among adults with HF, researchers reported in a meta-analysis.

Dapagliflozin reduces risk for worsening heart failure and cardiovascular death in adults with heart failure with mildly reduced or preserved ejection fraction, regardless of baseline HbA1c, according to findings from the DELIVER trial.

Both men and women with HF faced higher risks for depression and death by suicide in the first 3 months after their diagnosis, researchers reported in JACC: Heart Failure.

Effect of electronic alert system for HF on all-cause mortality and 30-day risk for HF rehospitalization.

IV acetazolamide or placebo for decongestion in patients with acute decompensated HF on loop diuretics.